Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17p)

被引：0

作者：

Jain, Nitin ^{[1
]}

Thompson, Philip ^{[1
]}

Burger, Jan A. ^{[1
]}

Borthakur, Gautam ^{[1
]}

Bose, Prithviraj ^{[1
]}

Estrov, Zeev ^{[1
]}

Ferrajoli, Alessandra ^{[1
]}

Gandhi, Varsha ^{[1
]}

Plunkett, William ^{[1
]}

Lopez, Wanda ^{[1
]}

Kantarjian, Hagop ^{[1
]}

O'Brien, Susan ^{[2
]}

Keating, Michael ^{[1
]}

Wierda, William ^{[3
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, NJ USA

[3] Univ Texas, Houston, TX USA

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

164

引用

页码：158 / 159

页数：2

共 50 条

[1] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p).
Jain, Nitin
Thompson, Philip A.
Burger, Jan Andreas
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Gandhi, Varsha
Plunkett, William
Lopez, Wanda
Kantarjian, Hagop M.
O'Brien, Susan Mary
Keating, Michael J.
Wierda, William G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[2] IBRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (GA101) (IFCG) FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH MUTATED IGHV AND NON-DEL(17P)
Jain, N.
Thompson, P.
Burger, J.
Borthakur, G.
Bose, P.
Estrov, Z.
Ferrajoli, A.
Gandhi, V.
Plunkett, W.
Lopez, W.
Kantarjian, H.
O'Brien, S.
Keating, M.
Wierda, W.
HAEMATOLOGICA, 2017, 102 : 171 - 171
[3] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
Jain, Nitin
Thompson, Philip
Burger, Jan
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Takahashi, Koichi
Garg, Naveen
Wang, Xuemei
Gandhi, Varsha
Plunkett, William
Kanagal-Shamanna, Rashmi
Patel, Keyur
Lopez, Wanda
Kantarjian, Hagop
O'Brien, Susan
Keating, Michael
Wierda, William
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S13 - S14
[4] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Nitin Jain
Philip Thompson
Jan Burger
Alessandra Ferrajoli
Koichi Takahashi
Zeev Estrov
Gautam Borthakur
Prithviraj Bose
Tapan Kadia
Naveen Pemmaraju
Koji Sasaki
Marina Konopleva
Elias Jabbour
Naveen Garg
Xuemei Wang
Rashmi Kanagal-Shamanna
Keyur Patel
Wei Wang
Jeffrey Jorgensen
Sa Wang
Wanda Lopez
Ana Ayala
William Plunkett
Varsha Gandhi
Hagop Kantarjian
Susan O’Brien
Michael Keating
William G. Wierda
Leukemia, 2021, 35 : 3421 - 3429
[5] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
Jain, Nitin
Thompson, Philip
Burger, Jan
Ferrajoli, Alessandra
Takahashi, Koichi
Estrov, Zeev
Borthakur, Gautam
Bose, Prithviraj
Kadia, Tapan
Pemmaraju, Naveen
Sasaki, Koji
Konopleva, Marina
Jabbour, Elias
Garg, Naveen
Wang, Xuemei
Kanagal-Shamanna, Rashmi
Patel, Keyur
Wang, Wei
Jorgensen, Jeffrey
Wang, Sa
Lopez, Wanda
Ayala, Ana
Plunkett, William
Gandhi, Varsha
Kantarjian, Hagop
O'Brien, Susan
Keating, Michael
Wierda, William G.
LEUKEMIA, 2021, 35 (12) : 3421 - 3429
[6] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Jain, Nitin
Thompson, Philip A.
Burger, Jan A.
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev
Ferrajoli, Alessandra
Takahashi, Koichi
Garg, Naveen
Wang, Xuemei
Gandhi, Varsha
Plunkett, William
Kanagal-Shamanna, Rashmi
Patel, Keyur
Lopez, Wanda
Kantarjian, Hagop M.
O'Brien, Susan M.
Keating, Michael J.
Wierda, William G.
BLOOD, 2017, 130
[7] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
Jain, Nitin
Thompson, Philip A.
Burger, Jan A.
Ferrajoli, Alessandra
Takahashi, Koichi
Estrov, Zeev E.
Borthakur, Gautam M.
Bose, Prithviraj
Kadia, Tapan M.
Pemmaraju, Naveen
Sasaki, Koji
Garg, Naveen
Wang, Xuemei
Kanagal-Shamanna, Rashmi
Patel, Keyur
Jorgensen, Jeffrey L.
Wang, Sa A.
Lopez, Wanda
Ayala, Ana
Plunkett, William
Gandhi, Varsha
Kantarjian, Hagop M.
O'Brien, Susan
Keating, Michael J.
Wierda, William G.
BLOOD, 2019, 134
[8] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients With CLL With Mutated IGHV and Without TP53 Aberration
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 6 - 8
[9] Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab ( iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses
Jain, Nitin
Thompson, Philip
Jain, Akhil
Burger, Jan A.
Ferrajoli, Alessandra
Senapati, Jayastu
Takahashi, Koichi
Swaminathan, Mahesh
Estrov, Zeev
Borthakur, Gautam
Bose, Prithviraj
Kadia, Tapan M.
Pemmaraju, Naveen
Sasaki, Koji
Bansal, Divyam
Konopleva, Marina Y.
Jabbour, Elias
Garg, Naveen
Wang, Xuemei
Kanagal-Shamanna, Rashmi
Patel, Keyur P.
Wang, Wei
Wang, Sa A.
Jorgensen, Jeffrey L.
Lopez, Wanda
Ayala, Ana
Plunkett, William
Gandhi, Varsha
Kantarjian, Hagop M.
O'Brien, Susan M.
Keating, Michael J.
Wierda, William G.
BLOOD, 2023, 142
[10] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Jain, Nitin
Thompson, Philip A.
Burger, Jan A.
Ferrajoli, Alessandra
Borthakur, Gautam
Bose, Prithviraj
Estrov, Zeev E.
Kadia, Tapan M.
Takahashi, Koichi
Garg, Naveen
Wang, Xuemei
Kanagal-Shamanna, Rashmi
Patel, Keyur
Lopez, Wanda
Ayala, Ana
Plunkett, William
Gandhi, Varsha
Kantarjian, Hagop M.
O'Brien, Susan M.
Keating, Michael J.
Wierda, William G.
BLOOD, 2018, 132

← 1 2 3 4 5 →